Following the resignation of John Johnson last month, US drug major Eli Lilly (NYSE: LLY) has promoted Sue Mahony, currently senior vice president of human resources and diversity, to the post of senior vice president and president of Lilly Oncology.
In this new role she continues to report to John Lechleiter, Lilly chairman, president and chief executive, and she remains a member of the company's executive committee.
Being promoted into Ms Mahony's former role is Steve Fry, currently VP of human resources for two of Lilly's business areas, bio-medicines and emerging markets. Fry now joins Lilly's executive leadership team and reports to Dr Lechleiter. Both moves are effective immediately, the company announced on Friday.
Ms Mahony joined Lilly more than 10 years ago after a decade in sales and marketing roles in the UK and Europe in oncology/hematology and cardiovascular medicine for Amgen, Bristol-Myers Squibb and Schering-Plough. She was named general manager of Lilly Canada in 2008 after roles in global marketing and new product development.
Smith & Nephew poaches Fabre chief
Meantime, the UK’s medical device company Smith & Nephew has appointed French drugmaker Pierre Fabre’s chief executive Olivier Bohuon as its own CEO, to replace David Illingworth, who has unexpectedly stepped down from the post for personal reasons and a wish to return to the USA.
As yet, the independent French company has not announced a replacement for Mr Bohuon, who only took over as head of the company, including becoming its president, last September. He joined Fabre from Abbott Laboratories.
Simcere appoints Industry veteran to sales/marketing head
Separately, Simcere Pharmaceutical (NYSE: SCR), a company specializing in the development, manufacturing, and marketing of branded and proprietary drugs in China, has appointed of Hong Zhao as its executive vice president of sales and marketing, effective February 12, 2011.
"Mr Zhao is highly respected in the Chinese pharmaceutical industry," said Jinsheng Ren, chairman and CEO of Simcere, adding: "Mr Zhao has nearly 20 years' experience in the pharmaceutical industry with a proven track record of leadership and performance. We warmly welcome Mr Zhao who will help strengthen our leadership team and better position our business for sustainable growth."
Mr Zhao joined the industry in 1992. He started as a pharmaceutical sales representative and took on positions of increasing responsibilities in sales and marketing with Xian Janssen and Novartis China. He most recently held the position of senior VP of Novartis Greater China and general manager of Novartis Shanghai.
No comments:
Post a Comment